Journal article
Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease
JM Kang, SY Lee, S Seo, HJ Jeong, SH Woo, H Lee, YB Lee, BK Yeon, DH Shin, KH Park, H Kang, N Okamura, S Furumoto, K Yanai, VL Villemagne, JK Seong, DL Na, T Ido, J Cho, KM Lee Show all
Neurobiology of Aging | ELSEVIER SCIENCE INC | Published : 2017
Abstract
This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with a..
View full abstractGrants
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
This study was supported by a grant from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare of the Republic of Korea (grant No: HI14C1135).